Disease Damage Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Systemic Lupus Erythematosus

REFERENCES

1. 1.↵
   1. Asanuma Y,
   2. Oeser A,
   3. Shintani AK,
   4. Turner E,
   5. Olsen N,
   6. Fazio S,
   7. et al.

   Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2407–15.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Urowitz MB,
   2. Ibanez D,
   3. Gladman DD

   . Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007;34:70–5.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Urowitz MB,
   2. Gladman D,
   3. Ibanez D,
   4. Fortin P,
   5. Sanchez-Guerrero J,
   6. Bae S,
   7. et al;
   8. Systemic Lupus International Collaborating Clinics

   . Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort. Arthritis Rheum 2008;59:176–80.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Karp I,
   2. Abrahamowicz M,
   3. Fortin PR,
   4. Pilote L,
   5. Neville C,
   6. Pineau CA,
   7. et al.

   Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 2008;59:169–75.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Magder LS,
   2. Petri M

   . Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012;176:708–19.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Abu-Shakra M,
   2. Urowitz MB,
   3. Gladman DD,
   4. Gough J

   . Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 1995;22:1259–64.

   OpenUrlPubMed
7. 7.↵
   1. Schoenfeld SR,
   2. Kasturi S,
   3. Costenbader KH

   . The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013;43:77–95.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Manzi S,
   2. Meilahn EN,
   3. Rairie JE,
   4. Conte CG,
   5. Medsger TA Jr,
   6. Jansen-McWilliams L,
   7. et al.

   Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408–15.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. D’Agostino RB Sr,
   2. Vasan RS,
   3. Pencina MJ,
   4. Wolf PA,
   5. Cobain M,
   6. Massaro JM,
   7. et al.

   General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117:743–53.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Conroy RM,
    2. Pyorala K,
    3. Fitzgerald AP,
    4. Sans S,
    5. Menotti A,
    6. De Backer G,
    7. et al;
    8. SCORE project group

    . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24:987–1003.

    OpenUrlCrossRefPubMed
11. 11.↵
    1. Piepoli MF,
    2. Hoes AW,
    3. Agewall S,
    4. Albus C,
    5. Brotons C,
    6. Catapano AL,
    7. et al.

    2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;252:207–74.

    OpenUrl
12. 12.↵
    1. Goldberg RJ,
    2. Urowitz MB,
    3. Ibanez D,
    4. Nikpour M,
    5. Gladman DD

    . Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol 2009;36:2454–61.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Esdaile JM,
    2. Abrahamowicz M,
    3. Grodzicky T,
    4. Li Y,
    5. Panaritis C,
    6. du Berger R,
    7. et al.

    Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001;44:2331–7.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. O’Neill SG,
    2. Pego-Reigosa JM,
    3. Hingorani AD,
    4. Bessant R,
    5. Isenberg DA,
    6. Rahman A

    . Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. Rheumatology 2009;48:573–5.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Corrales A,
    2. Parra JA,
    3. González-Juanatey C,
    4. Rueda-Gotor J,
    5. Blanco R,
    6. Llorca J,
    7. et al.

    Cardiovascular risk stratification in rheumatic diseases: carotid ultrasound is more sensitive than Coronary Artery Calcification Score to detect subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2013;72:1764–70.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Corrales A,
    2. Gonzalez-Juanatey C,
    3. Peiro ME,
    4. Blanco R,
    5. Llorca J,
    6. Gonzalez-Gay MA

    . Carotid ultrasound is useful for the cardiovascular risk stratification of patients with rheumatoid arthritis: results of a population-based study. Ann Rheum Dis 2014;73:722–7.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Agca R,
    2. Heslinga SC,
    3. Rollefstad S,
    4. Heslinga M,
    5. McInnes IB,
    6. Peters MJ,
    7. et al.

    EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017;76:17–28.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Hochberg MC

    . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Gladman DD,
    2. Ibanez D,
    3. Urowitz MB

    . Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288–91.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. Gladman D,
    2. Ginzler E,
    3. Goldsmith C,
    4. Fortin P,
    5. Liang M,
    6. Urowitz M,
    7. et al.

    The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363–9.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Mosca M,
    2. Bombardieri S

    . Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol 2006;6 Suppl 43:S-99–104.

    OpenUrl
22. 22.↵
    1. Katz JD,
    2. Senecal JL,
    3. Rivest C,
    4. Goulet JR,
    5. Rothfield N

    . A simple severity of disease index for systemic lupus erythematosus. Lupus 1993;2:119–23.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Touboul PJ,
    2. Hennerici MG,
    3. Meairs S,
    4. Adams H,
    5. Amarenco P,
    6. Bornstein N,
    7. et al.

    Mannheim carotid intima-media thickness consensus (2004–2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, and Brussels, Belgium, 2006. Cerebrovasc Dis 2007;23:75–80.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Piepoli MF,
    2. Hoes AW,
    3. Agewall S,
    4. Albus C,
    5. Brotons C,
    6. Catapano AL,
    7. et al;
    8. ESC Scientific Document Group

    . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2315–81.

    OpenUrlCrossRefPubMed
25. 25.↵
    1. Roman MJ,
    2. Shanker BA,
    3. Davis A,
    4. Lockshin MD,
    5. Sammaritano L,
    6. Simantov R,
    7. et al.

    Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399–406.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Thompson T,
    2. Sutton-Tyrrell K,
    3. Wildman RP,
    4. Kao A,
    5. Fitzgerald SG,
    6. Shook B,
    7. et al.

    Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus. Arthritis Rheum 2008;58:835–42.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Kao AH,
    2. Lertratanakul A,
    3. Elliott JR,
    4. Sattar A,
    5. Santelices L,
    6. Shaw P,
    7. et al.

    Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. Am J Cardiol 2013;112:1025–32.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Fernandez-Nebro A,
    2. Rua-Figueroa I,
    3. Lopez-Longo FJ,
    4. Galindo-Izquierdo M,
    5. Calvo-Alen J,
    6. Olive-Marques A,
    7. et al;
    8. EAS-SER (Systemic Diseases Study Group of Spanish Society of Rheumatology)

    . Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry. Medicine 2015;94:e1183.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Zhang M,
    2. Qi C,
    3. Cao L,
    4. Qian J,
    5. Ni Z

    . Metabolic syndrome is correlated with carotid atherosclerosis in patients with lupus nephritis. Am J Med Sci 2014;348:486–91.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Sanchez-Perez H,
    2. Tejera-Segura B,
    3. de Vera-Gonzalez A,
    4. Gonzalez-Delgado A,
    5. Olmos JM,
    6. Hernandez JL,
    7. et al.

    Insulin resistance in systemic lupus erythematosus patients: contributing factors and relationship with subclinical atherosclerosis. Clin Exp Rheumatol 2017;35:885–92.

    OpenUrl
31. 31.↵
    1. Bruce IN,
    2. Urowitz MB,
    3. Gladman DD,
    4. Ibanez D,
    5. Steiner G

    . Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003;48:3159–67.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Crowson CS,
    2. Gabriel SE,
    3. Semb AG,
    4. van Riel PL,
    5. Karpouzas G,
    6. Dessein PH,
    7. et al;
    8. Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis

    . Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries. Rheumatology 2017;56:1102–10.

    OpenUrlCrossRefPubMed
33. 33.↵
    1. Rueda-Gotor J,
    2. Llorca J,
    3. Corrales A,
    4. Parra JA,
    5. Portilla V,
    6. Genre F,
    7. et al.

    Cardiovascular risk stratification in axial spondyloarthritis: carotid ultrasound is more sensitive than coronary artery calcification score to detect high-cardiovascular risk axial spondyloarthritis patients. Clin Exp Rheumatol 2018;36:73–80.

    OpenUrl
34. 34.↵
    1. Rua-Figueroa I,
    2. Arencibia-Mireles O,
    3. Elvira M,
    4. Erausquin C,
    5. Ojeda S,
    6. Francisco F,
    7. et al.

    Factors involved in the progress of preclinical atherosclerosis associated with systemic lupus erythematosus: a 2-year longitudinal study. Ann Rheum Dis 2010;69:1136–9.

    OpenUrlAbstract/FREE Full Text
35. 35.↵
    1. Capuano V,
    2. D’Arminio T,
    3. La Sala G,
    4. Mazzotta G

    . The third component of the complement (C3) is a marker of the risk of atherogenesis. Eur J Cardiovasc Prev Rehabil 2006;13:658–60.

    OpenUrl
36. 36.↵
    1. Engstrom G,
    2. Hedblad B,
    3. Janzon L,
    4. Lindgarde F

    . Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: a population-based cohort study. Eur J Cardiovasc Prev Rehabil 2007;14:392–7.

    OpenUrlCrossRefPubMed
37. 37.↵
    1. van Greevenbroek MM,
    2. Jacobs M,
    3. van der Kallen CJ,
    4. Vermeulen VM,
    5. Jansen EH,
    6. Schalkwijk CG,
    7. et al.

    The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study). Eur J Clin Invest 2011;41:372–9.

    OpenUrlCrossRefPubMed
38. 38.↵
    1. Wlazlo N,
    2. van Greevenbroek MM,
    3. Ferreira I,
    4. Jansen EJ,
    5. Feskens EJ,
    6. van der Kallen CJ,
    7. et al.

    Low-grade inflammation and insulin resistance independently explain substantial parts of the association between body fat and serum C3: the CODAM study. Metabolism 2012;61:1787–96.

    OpenUrlCrossRefPubMed
39. 39.↵
    1. Nilsson B,
    2. Hamad OA,
    3. Ahlstrom H,
    4. Kullberg J,
    5. Johansson L,
    6. Lindhagen L,
    7. et al.

    C3 and C4 are strongly related to adipose tissue variables and cardiovascular risk factors. Eur J Clin Invest 2014;44:587–96.

    OpenUrlCrossRef
40. 40.↵
    1. Petri M,
    2. Spence D,
    3. Bone LR,
    4. Hochberg MC

    . Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine 1992;71:291–302.

    OpenUrlCrossRefPubMed